Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eton Pharmaceuticals (ETON) Gains from Investment Securities: 2019-2025

Historic Gains from Investment Securities for Eton Pharmaceuticals (ETON) over the last 5 years, with Sep 2025 value amounting to $28,000.

  • Eton Pharmaceuticals' Gains from Investment Securities fell 84.36% to $28,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.8 million, marking a year-over-year increase of 321.26%. This contributed to the annual value of $5.9 million for FY2024, which is 22.31% up from last year.
  • Latest data reveals that Eton Pharmaceuticals reported Gains from Investment Securities of $28,000 as of Q3 2025, which was down 65.43% from $81,000 recorded in Q2 2025.
  • Over the past 5 years, Eton Pharmaceuticals' Gains from Investment Securities peaked at $4.6 million during Q1 2022, and registered a low of $2,000 during Q1 2024.
  • In the last 3 years, Eton Pharmaceuticals' Gains from Investment Securities had a median value of $73,500 in 2023 and averaged $278,875.
  • As far as peak fluctuations go, Eton Pharmaceuticals' Gains from Investment Securities skyrocketed by 91,550.00% in 2021, and later plummeted by 98.90% in 2024.
  • Quarterly analysis of 5 years shows Eton Pharmaceuticals' Gains from Investment Securities stood at $181,000 in 2021, then spiked by 67.02% to $157,000 in 2022, then slumped by 57.96% to $66,000 in 2023, then spiked by 2,454.55% to $1.7 million in 2024, then slumped by 84.36% to $28,000 in 2025.
  • Its last three reported values are $28,000 in Q3 2025, $81,000 for Q2 2025, and $8,000 during Q1 2025.